Cancer Discovery, Journal Year: 2024, Volume and Issue: 14(5), P. 698 - 700
Published: May 1, 2024
Summary: In this issue, Rubinson, Tanaka, and colleagues demonstrate that differences among G12C inhibitors rely on their ability to covalently bind not only mutant KRAS but also NRAS HRAS, proposing sotorasib as a potent inhibitor. See related article by Rubinson et al., p. 727 (6).
Language: Английский
Cancers, Journal Year: 2024, Volume and Issue: 16(12), P. 2211 - 2211
Published: June 13, 2024
Among professional antigen-presenting cells, dendritic cells (DCs) orchestrate innate and adaptive immunity play a pivotal role in anti-tumor immunity. DCs are heterogeneous population with varying functions the tumor microenvironment (TME). Tumor-associated differentiate developmentally functionally into three main subsets: conventional (cDCs), plasmacytoid (pDCs), monocyte-derived (MoDCs). There two major subsets of cDCs TME, cDC1 cDC2. is critical for cross-presenting antigens to activate cytotoxic CD8+ T also required priming earlier CD4+ certain solid tumors. cDC2 vital multiple models. pDC unique subset produces type I IFN through TLR7 TLR9. Studies have shown that pDCs related immunosuppression TME secretion immunosuppressive cytokines by promoting regulatory cells. MoDCs separately from monocytes response inflammatory cues infection. Also, can cross-prime In this review, we summarize DCs. We discuss different DC shaping cell targeting potential immunotherapeutic benefits against cancer.
Language: Английский
Citations
17
Current Oncology, Journal Year: 2024, Volume and Issue: 31(4), P. 2024 - 2046
Published: April 3, 2024
KRAS is a small GTPase that among the most commonly mutated oncogenes in cancer. Here, we discuss biology, therapeutic avenues to target it, and mechanisms of resistance tumors employ response inhibition. Several strategies are under investigation for inhibiting oncogenic KRAS, including molecule compounds targeting specific mutations, pan-KRAS inhibitors, PROTACs, siRNAs, PNAs, mutant KRAS-specific immunostimulatory strategies. A central challenge effectiveness frequent development these treatments. Direct can involve mutations reduce drug efficacy or copy number alterations increase expression KRAS. Indirect arise from rescue KRAS-dependent cells either by reactivating same signaling via alternative pathways. Further, non-mutational forms take form epigenetic marks, transcriptional reprogramming, within tumor microenvironment. As possible inhibit expand, understanding nuances paramount both enhanced therapeutics innovative combinations.
Language: Английский
Citations
13
RSC Advances, Journal Year: 2024, Volume and Issue: 14(45), P. 33429 - 33448
Published: Jan. 1, 2024
In this review, we wish to compile examples of chiral medicines approved by the FDA in years 2022 and 2023 with an emphasis on their synthesis along information induction as well enantiomeric excess.
Language: Английский
Citations
13
Cells, Journal Year: 2024, Volume and Issue: 13(5), P. 436 - 436
Published: March 1, 2024
Lung cancer remains a formidable global health challenge that necessitates inventive strategies to improve its therapeutic outcomes. The conventional treatments, including surgery, chemotherapy, and radiation, have demonstrated limitations in achieving sustained responses. Therefore, exploring novel approaches encompasses range of interventions show promise enhancing the outcomes for patients with advanced or refractory cases lung cancer. These groundbreaking can potentially overcome resistance offer personalized solutions. Despite rapid evolution emerging therapies, persistent challenges such as resistance, toxicity, patient selection underscore need continued development. Consequently, landscape therapy is transforming introduction precision medicine, immunotherapy, innovative modalities. Additionally, multifaceted approach involving combination therapies integrating targeted agents, immunotherapies, traditional cytotoxic treatments addresses heterogeneity while minimizing adverse effects. This review provides brief overview latest are reshaping treatment. As these progress through clinical trials integrated into standard care, potential more effective, targeted, comes focus, instilling renewed hope facing challenging diagnoses.
Language: Английский
Citations
10
Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101179 - 101179
Published: Jan. 1, 2025
Language: Английский
Citations
1
Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155954 - 155954
Published: April 1, 2025
Language: Английский
Citations
1
Lung Cancer, Journal Year: 2024, Volume and Issue: 190, P. 107510 - 107510
Published: Feb. 24, 2024
Language: Английский
Citations
7
Published: Jan. 24, 2024
Lung cancer remains a formidable global health challenge that necessitates inventive strategies to improve therapeutic outcomes. Conventional treatments, including surgery, chemotherapy, and radiation, have demonstrated limitations in achieving sustained responses. Therefore, the explora-tion of novel approaches encompasses range interventions show promise enhancing outcomes for patients with lung cancer, particularly those facing advanced or refractory cases. These groundbreaking hold potential overcome resistance offer personalized solutions. Despite rapid evolution emerging therapies, persistent challenges such as resistance, toxicity, patient selection underscore need continued development. Consequently, landscape therapy is transforming in-troduction precision medicine, immunotherapy, innovative modalities. Addi-tionally, multifaceted approach involving combination therapies through integration tar-geted agents, immunotherapies, traditional cytotoxic treatments addresses heterogeneity while minimizing adverse effects. This review provides brief overview latest are reshaping treatment. As these progress clinical trials integrate into standard care, more effective, targeted, comes focus, instilling renewed hope challenging diagnoses.
Language: Английский
Citations
5
Pharmacological Research, Journal Year: 2024, Volume and Issue: unknown, P. 107465 - 107465
Published: Oct. 1, 2024
Language: Английский
Citations
4
Annals of Pharmacotherapy, Journal Year: 2023, Volume and Issue: 58(6), P. 622 - 635
Published: Sept. 12, 2023
Objective: To evaluate the safety and efficacy of novel KRAS-targeting agents, sotorasib adagrasib, in treating KRAS G12C-mutated non–small cell lung cancer (NSCLC). Data Sources: A comprehensive English-based literature search PubMed Clinicaltrials.gov between January 2000 July 2023 was conducted using terms sotorasib, Lumakras, AMG 510, Krazati, MRTX849. Study Selection Extraction: Relevant prescribing information, clinical trials, treatment guidelines were evaluated. Synthesis: Sotorasib adagrasib received accelerated US Food Drug Administration (FDA) approval following pivotal phase I/II trials. Sotorasib, a first-in-class inhibitor, demonstrated an overall response rate (ORR) 41% progression-free survival (PFS) 6.3 months. In III confirmatory trial, showed significantly longer PFS compared with docetaxel (5.6 vs. 4.5 months; P = 0.0017). Adagrasib produced ORR 42.9% 6.5 Both drugs present unique profiles, common toxicities, including diarrhea, musculoskeletal pain, fatigue, hepatotoxicity. Relevance to Patient Care Clinical Practice: With mutations being among most oncogenic alterations NSCLC, offer new therapeutic avenues for this previously “undruggable” target. Current list as second-line options patients confirmed NSCLC. Additional studies are required further differentiate profiles these 2 agents identify their optimal place therapy. Conclusion: promising outcomes targeting constitutively active G12C driver, underscoring need research optimize application high-risk population.
Language: Английский
Citations
10